Table 6 Base-case parameters and values used in sensitivity analysis
Base-case | Sensitivity analysis | ||
|---|---|---|---|
Prevalence: ±30% | |||
12.7 per 100,000 | 6.4 per 100,000 | 19.1 per 100,000 | |
Patients treated with prophylaxis: ±25% | |||
55% | 41% | 69% | |
rFVIIIFc uptake rate: −50%; + 25% | |||
Year 1 | 10% | 5% | 12.5% |
Year 2 | 15% | 7.5% | 18.8% |
Year 3 | 20% | 10% | 25% |
rFVIIIFc dosage (IU/Kg): ±30% | |||
Paediatric patients | 44.1 | 30.8 | 57.3 |
Adult patients | 38.95 | 27.3 | 50.6 |
Dosage of conventional products (IU/Kg): ±30% | |||
Paediatric patients | 33.8 | 23.7 | 43.9 |
Adult patients | 43 | 30.1 | 55.9 |
Products cost (Euro/IU): −15% rFVIIIFc;– 15% conventional products | |||
rFVIIIFc | 0.72 | 0.61 | 0.72 |
Advate® | 0.65 | 0.65 | 0.55 |
Kogenate® | 0.69 | 0.69 | 0.59 |
Refacto® | 0.69 | 0.69 | 0.59 |
Helixate® | 0.69 | 0.69 | 0.59 |
Recombinate® | 0.60 | 0.60 | 0.51 |
Plasma-derived product | 0.60 | 0.60 | 0.51 |